Soliris® (eculizumab) – New indication
October 23, 2017 – Alexion announced the FDA approval of Soliris (eculizumab) for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive.
Download PDF
